Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

@article{Fox2015PharmacokineticAP,
  title={Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors},
  author={Elizabeth Fox and Brigitte C Widemann and Devang Pastakia and Clara C. Chen and Sherry X. Yang and Diane E. Cole and Frank M Balis},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2015},
  volume={76},
  pages={1273-1283}
}
P-glycoprotein (Pgp), an ATP-dependent transport protein, confers multidrug resistance in cancer cells. Tariquidar binds and inhibits Pgp. To assess the toxicity, pharmacokinetics (PK), and pharmacodynamics of tariquidar, we conducted a phase I trial of tariquidar in combination with doxorubicin, docetaxel, or vinorelbine in children and adolescents with recurrent or refractory solid tumors. Patients less than 19 years of age with refractory or recurrent solid tumors were eligible. Tariquidar… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS